Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. reports successful dosing of the first participants in a Phase I/II clinical trial for its synthetic anti-infective, RECCE 327, at the highest dosage yet of 4,000mg. The trial investigates various infusion rates of the potential UTI/Urosepsis treatment, with an emphasis on determining the Minimum Inhibitory Concentration (MIC) against bacteria for regulatory approval. The outcome of the trial, which is part of Recce’s efforts to combat antibiotic-resistant superbugs, is eagerly anticipated.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
